Evidence map›Paper›PMID 40575346›Full record

ReviewRegenerative therapy2025

Mesenchymal stem cell for hemorrhagic stroke: A clinical review.

Silvia de la Calle, Mercedes Zurita

Abstract readReview
In one paragraph

Review in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Silvia de la CalleCell Therapy Unit, Puerta de Hierro Hospital, Majadahonda, Madrid, 28222 Spain.
Mercedes ZuritaCell Therapy Unit Responsable, Puerta de Hierro Hospital, Majadahonda, Madrid, 28222 Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemorrhagic stroke, which is also called an intracerebral hemorrhage, is a cerebrovascular disease that represents a serious public health problem worldwide. Among all types of stroke, intracerebral hemorrhage causes the highest percentage of mortality and morbidity, affecting 2 million people annually, with no specific treatment established except for rehabilitation-oriented techniques. In recent years, new alternatives have been sought to treat this type of pathology, with mesenchymal stem cell therapy gaining special relevance. These cells present a series of biological properties, including regenerative repair, neuroprotection, and immunomodulation that make them a tool with enormous potential in regenerative medicine. In this review, we are going to focus on clinical trials and clinical studies which use cell therapy with Mesenchymal Stem Cells as a treatment for patients suffering from intracerebral hemorrhage. The clinical trials found are not very numerous. It remains an area to be explored; however, existing studies suggest it is a safe therapy that yields positive neurological and functional outcomes in many treated patients. All of this makes it a very promising and encouraging therapy for patients with this type of pathology.

Indexed as

Cell therapyHemorrhagic strokeIntracerebral hemorrhageMesenchymal stem cells and clinical trials

Identifiers

PMID40575346
PMCPMC12197982

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.